Related Experiment Videos
Developments in 5-hydroxytryptamine receptor pharmacology in migraine
1Department of Neurology, Stanford University Medical Center, California.
Neurologic Clinics
|November 1, 1990
Summary
Migraine treatment may be advanced by understanding how drugs interact with serotonin (5-HT) receptors. Acute drugs target 5-HT1D receptors, while prophylactic drugs may target 5-HT2 and 5-HT1C receptors.
Area of Science:
- Neuroscience
- Pharmacology
- Neurology
Background:
- Migraine pathogenesis remains unclear due to a lack of suitable animal models.
- Clinical data over 30 years suggests specific serotonin (5-HT) receptor subtypes play a role in migraine pathophysiology.
- Effective antimigraine agents interact with various 5-HT receptor subtypes in the human brain.
Purpose of the Study:
- To elucidate the role of specific 5-HT receptor subtypes in migraine pathophysiology.
- To identify a common mechanism of action for effective antimigraine agents.
- To propose a novel approach for analyzing antimigraine agents based on receptor selectivity.
Main Methods:
- Review of clinical data spanning 30 years on antimigraine agents and their interaction with 5-HT receptor subtypes.
- Analysis of the affinity of acute and prophylactic antimigraine drugs for specific 5-HT receptors (5-HT1D, 5-HT1A, 5-HT2, 5-HT1C).
- Theoretical consideration of receptor-mediated mechanisms in migraine progression and inflammation.
Main Results:
- Acute antimigraine drugs (ergots, sumatriptan) exhibit high affinity for 5-HT1D receptors and lower affinity for 5-HT1A receptors, located on intracranial blood vessels and nerve terminals.
- Prophylactic antimigraine drugs show high affinity for 5-HT2 and 5-HT1C receptors, which are widespread in the nervous system and involved in neuronal depolarization and inflammation.
- 5-HT1D receptor agonists may inhibit the release of vasoactive substances, potentially halting migraine progression.
- 5-HT2 antagonists may protect against perivascular inflammation, explaining their prophylactic efficacy.
Conclusions:
- Clinical data supports the involvement of 5-HT1D, 5-HT1A, 5-HT2, and 5-HT1C receptors in migraine pathophysiology.
- Understanding receptor interactions provides a novel framework for selecting and evaluating antimigraine therapies.
- Future research should focus on agents with specific 5-HT receptor subtype selectivity to further elucidate migraine mechanisms.